Valo Health Taps Dr. Chris Anagnostopoulos as Chief Causal AI Officer

Valo Health Inc., a pioneer in the use of human data and AI to accelerate drug discovery and development, has appointed Chris Anagnostopoulos, PhD, C.Stat, to the newly created position of Chief Causal AI Officer.

In this role, Anagnostopoulos will lead the advancement of Valo’s human causal biology platform, translating large-scale, real‑world human data into causal insights that inform drug discovery.

“The creation of this position and strategic appointment underscore the importance we place on human causal evidence as the foundation of drug discovery, and the opportunity we see for causal AI/ML tools to help solve the translational gap,” said Brian Alexander, MD, MPH, CEO of Valo Health. “Dr. Anagnostopoulos brings an exceptionally rare skill set at the intersection of AI, statistics, and human biology. His expertise will be instrumental as we continue scaling this capability, enabling a new era of drug discovery that is anchored in human causal biology.”

Valo also recently named a new CSO, Karin Conde-Knape.

Experience

Anagnostopoulos is a seasoned AI and life sciences innovation leader with more than two decades of experience spanning academia, global consulting, technology startups, and leading biopharmaceutical companies.

He joins Valo from QuantumBlack, AI by McKinsey, where he served as Tech Fellow Partner, Global Director of AI Innovation in Life Sciences, and co‑founder of McKinsey’s Scientific AI service line, driving the application of causal machine learning and advanced analytics across biopharma R&D. Previously, Anagnostopoulos held senior leadership roles at the technology unicorn Improbable and was also an Associate Professor at Imperial College London.

Anagnostopoulos was a Research Fellow in the Statistical Laboratory at Cambridge University, and holds a PhD in Statistics from Imperial College London, as well as two MSc degrees, one in Machine Learning from the University of Edinburgh, and one in Theoretical Computer Science from the University of Athens. He earned his undergraduate degree in Mathematics at Cambridge University. He is a Chartered Statistician (C.Stat) of the Royal Statistical Society and currently serves as an Honorary Associate Professor at Imperial College London.

“Drug discovery is struggling with a widening clinical translation gap, which consistently drives low clinical trial success rates, despite a growing number of drug candidates,” remarked Anagnostopoulos. “Addressing this causal gap requires integrating human causal biology insights as early as possible in drug discovery. Valo’s platform represents a truly differentiated way to do this, extracting causal mechanisms of disease from deep human data. I’m thrilled to join this talented team and work together to fully leverage causal AI to advance human health.”